Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
ALCAFTADINE vs NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine/Decongestant
"Phentermine may decrease the sedative activities of Alcaftadine."